Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B-100:: the MEDPED Slovakia project

被引:6
作者
Vohnout, B
Raslová, K
Gasparovic, J
Franeková, J
Fábryová, L
Belosovicová, M
Kovác, G
Sebová, C
Rajecová, E
Stavny, J
Babjak, M
Donati, MB
Iacoviello, L
机构
[1] Inst Prevent & Clin Med, Bratislava 83301, Slovakia
[2] OKB NsP Zilina, Bratislava, Slovakia
[3] NsP Milosrdni Bratia, Bratislava, Slovakia
[4] DFNsP, Bratislava, Slovakia
[5] FNsP ADerera, Bratislava, Slovakia
[6] UTaRCH, Bratislava, Slovakia
[7] OKB NsP, Poprad, Slovakia
[8] OKB NsP, Humenne, Slovakia
[9] Catholic Univ, Ctr High Technol Res & Educ Biomed Sci, I-86100 Campobasso, Italy
[10] Consorzio Mario Negri Sud, Angela Valenti Lab Genet & Environm Risk Factors, Santa Maria Imbaro, Italy
关键词
familial hypercholesterolemia; familial defective Apo B-100; Apo E; polymorphism;
D O I
10.1016/S1567-5688(03)00023-0
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We examined, from a cohort of 165 families, 529 individuals for familial hypercholesterolemia (FH). Utilising clinical criteria for diagnosis, we identified 122 patients (n = 41 families) as having FH. With PCR testing, 31 individuals (n = 12 families) were found to have familial defective Apo B-100 (FDB). From the cohort, 102 normolipidemic (NL) individuals served as a control group. Patients with FH had the highest levels of total cholesterol (TC), LDL-cholesterol (LDL-C) and apolipoprotein B (Apo 13), followed by FDB patients and the normolipidemic relatives had the lowest levels (P < 0.0001 for all parameters). We did not find any effect of Apo E genotypes on lipid levels in the NL or FH group. Therefore, other genetic and/or environmental factors may be responsible for the diversity in the clinical expression in these populations. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:3 / 5
页数:3
相关论文
共 8 条
[1]   Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries [J].
Hansen, PS ;
Defesche, JC ;
Kastelein, JJP ;
Gerdes, LU ;
Fraza, L ;
Gerdes, C ;
Tato, F ;
Jensen, HK ;
Jensen, LG ;
Klausen, IC ;
Faergeman, O ;
Schuster, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (04) :741-747
[2]   GENETIC AND ENVIRONMENTAL-FACTORS AFFECTING THE INCIDENCE OF CORONARY-ARTERY DISEASE IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
HILL, JS ;
HAYDEN, MR ;
FROHLICH, J ;
PRITCHARD, PH .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (02) :290-297
[3]  
HIXSON JE, 1990, J LIPID RES, V31, P545
[4]   DIFFERENCES IN THE PHENOTYPIC CHARACTERISTICS OF SUBJECTS WITH FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 AND FAMILIAL HYPERCHOLESTEROLEMIA [J].
MISEREZ, AR ;
KELLER, U .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (10) :1719-1729
[5]   Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses:: Comparison to controls without personal and family history of atherosclerosis [J].
Raslová, K ;
Smolková, B ;
Vohnout, B ;
Gasparovic, J ;
Frohlich, JJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (01) :24-29
[6]   ALLELE-SPECIFIC AND ASYMMETRIC POLYMERASE CHAIN-REACTION AMPLIFICATION IN COMBINATION - A ONE-STEP POLYMERASE CHAIN-REACTION PROTOCOL FOR RAPID DIAGNOSIS OF FAMILIAL DEFECTIVE APOLIPOPROTEIN-B-100 [J].
SCHUSTER, H ;
RAUH, G ;
MULLER, S ;
KELLER, C ;
WOLFRAM, G ;
ZOLLNER, N .
ANALYTICAL BIOCHEMISTRY, 1992, 204 (01) :22-25
[7]  
*WHO FAM HYP, HUM GEN PROGR DEV NO, P1
[8]   DIAGNOSING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING NEW PRACTICAL CRITERIA VALIDATED BY MOLECULAR-GENETICS [J].
WILLIAMS, RR ;
HUNT, SC ;
SCHUMACHER, MC ;
HEGELE, RA ;
LEPPERT, MF ;
LUDWIG, EH ;
HOPKINS, PN .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (02) :171-176